What is claimed is:

1. A use of motesanib in the manufacture of a medicament for effectively increasing overall survival associated with nonsquamous non-small cell lung cancer in an Asian patient greater than that observed with a taxane and a platinum-containing anti-cancer drug alone, comprising treating the Asian patient with a combination of motesanib, a taxane and a platinum-containing anti-cancer drug.

2. The use of Claim 1 wherein the medicament increases overall survival when compared with treatment with paclitaxel and carboplatin.

3. The use of Claim 1 wherein the nonsquamous non-small cell lung cancer is advanced.

4. The use of Claim 1 wherein the nonsquamous non-small cell lung cancer is Stage IIIB, Stage IV or recurrent.

5. A use of motesanib in the manufacture of a medicament for effectively increasing progression free survival associated with nonsquamous non-small cell lung cancer in an Asian patient greater than that observed with a taxane and a platinum-containing anti-cancer drug alone, comprising treating the Asian patient with a combination of motesanib, a taxane and a platinum-containing anti-cancer drug.

6. The use of Claim 5 wherein the medicament increases progression free survival when compared with treatment with paclitaxel and carboplatin.

7. A use of motesanib in the manufacture of a medicament for effectively improving overall survival associated with nonsquamous non-small cell lung cancer in an Asian patient comprising treating the Asian patient with motesanib, a taxane and a platinum-containing anti-cancer drug.

~~8. The use of Claim 1 wherein the motesanib is administered in combination with one or more chemotherapeutic agents, provided the chemotherapeutic agent is not panitumumab.~~

~~9.~~8. The use of Claim 1 wherein the taxane is paclitaxel and the platinum-containing anti-cancer drug is carboplatin.

~~10.~~9. The use of ~~9~~ 8 wherein the paclitaxel is administered at 200 mg/m^2 .

~~11.~~10. The use of ~~9~~ 8 wherein the carboplatin is administered at a AUC 6 mg/mL•min.

~~12.~~11. The use of Claim 1, 5 or 7 wherein the nonsquamous non-small cell lung cancer is adenocarcinoma.

~~13.~~12. The use of Claim 1, 5 or 7 wherein the treatment is first line treatment.

~~14.~~13. The use of Claim 1, 5 or 7 wherein the motesanib is administered at a daily dose of 100 mg or 125 mg.

~~15.~~14. The use of Claim 1, 5 or 7 wherein the motesanib is administered at a daily dose of 125 mg.

~~16.~~15. The use of Claim 1, 5 or 7 wherein the Asian patient is of Japan, Republic of Korea, Taiwan, China, Hong Kong, Philippines, or Singapore ethnicity.

~~17.~~16. The use of Claim 1, 5 or 7 wherein the Asian patient is of Republic of Korea, Taiwan, China, Hong Kong, Philippines, or Singapore ethnicity.

~~18.~~17. The use of Claim 1, 5 or 7 wherein the Asian patient is Japanese.

~~19. A use of motesanib in the manufacture of a medicament for first line treatment of nonsquamous non-small cell lung cancer in a patient, wherein the patient is not of Non-Asian origin.~~